Therefore, a combined targeted inhibition of STAT1, PARP9, PARP14 and/or DTX3L could increase the efficacy of currently available treatment for prostate, DLBCL and other high-risk tumour types harbouring an increased STAT1 signalling. Here, STAT1 is linked to neoplasm.